Exploration of the P3 region of PEXEL peptidomimetics leads to a potent inhibitor of the Plasmodium protease, plasmepsin V.

Bioorg Med Chem

The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, 3010, Australia. Electronic address:

Published: May 2016

The use of arginine isosteres is a known strategy to overcome poor membrane permeability commonly associated with peptides or peptidomimetics that possess this highly polar amino acid. Here, we apply this strategy to peptidomimetics that are potent inhibitors of the malarial protease, plasmepsin V, with the aim of enhancing their activity against Plasmodium parasites, and exploring the structure-activity relationship of the P3 arginine within the S3 pocket of plasmepsin V. Of the arginine isosteres trialled in the P3 position, we discovered that canavanine was the ideal and that this peptidomimetic potently inhibits plasmepsin V, efficiently blocks protein export and inhibits parasite growth. Structure studies of the peptidomimetics bound to plasmepsin V provided insight into the structural basis for the enzyme activity observed in vitro and provides further evidence why plasmepsin V is highly sensitive to substrate modification.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2016.03.027DOI Listing

Publication Analysis

Top Keywords

protease plasmepsin
8
plasmepsin arginine
8
arginine isosteres
8
plasmepsin
6
exploration region
4
region pexel
4
peptidomimetics
4
pexel peptidomimetics
4
peptidomimetics leads
4
leads potent
4

Similar Publications

The antimalarial activity of transdermal N-89 mediated by inhibiting ERC gene expression in P. Berghei-infected mice.

Parasitol Int

December 2024

Division of International Infectious Diseases Control, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8530, Japan. Electronic address:

Through studies of new antimalarial drugs, we identified 1,2,6,7-tetraoxaspiro[7.11]nonadecane (N-89) as a potential drug candidate. Here, we analyzed the antimalarial action of a transdermal formulation (td) of N-89, designed for easy use by children, using Plasmodium berghei-infected mice as a model for malaria patients.

View Article and Find Full Text PDF

Molecular insights into the aspartate protease Plasmepsin II activity inhibition by fluoroquinolones: A pathway to antimalarial drug development.

Int J Biol Macromol

January 2025

UM-DAE Centre for Excellence in Basic Sciences, University of Mumbai, Vidyanagri Campus, Kalina, Mumbai 400098, India. Electronic address:

Plasmepsin II (PlmII) belongs to the aspartate proteases and is involved in hemoglobin degradation in Plasmodium falciparum. Due to its critical role in the survival of the Plasmodium, PlmII is considered as a potent drug target for antimalarial therapy. We have done recombinant protein production of pro-plasmepsin II (Pro-plmII).

View Article and Find Full Text PDF

Advances in protease inhibition-based chemotherapy: A decade of insights from Malaria research.

Adv Parasitol

October 2024

Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic; Faculty of Science, University of South Bohemia, Ceske Budejovice, Czech Republic.

Article Synopsis
  • Recent research on the parasite Plasmodium falciparum has advanced our understanding of protease isoenzymes, revealing their unique roles and biochemical features.
  • *The findings have led to new chemotherapy options that utilize low molecular weight inhibitors to target specific molecular sites within the parasite.
  • *Additionally, advancements in proteasome inhibition and research on vital metalloproteases are paving the way for the potential treatment and study of other lesser-known parasitic diseases.*
View Article and Find Full Text PDF
Article Synopsis
  • High off-target promiscuity and potent cytotoxicity in drug development can lead to a high failure rate, making safety assessment critical for compounds like novel plasmepsin X (PMX) inhibitors for malaria treatment.
  • A total of 249 PMX compounds were tested through various assays, revealing a correlation between high cytotoxicity in liver cells and poor tolerability in animal studies, often associated with specific receptor activities.
  • A structured approach using in vitro assays is necessary to identify harmful targets early and improve the chances of selecting safer compounds for further testing.
View Article and Find Full Text PDF

Quinoline-related antimalarial drugs have been associated with cardiotoxicity risk, in particular QT prolongation and QRS complex widening. In collaboration with Medicines for Malaria Venture, we discovered novel plasmepsin X (PMX) inhibitors for malaria treatment. The first lead compounds tested in anesthetized guinea pigs (GPs) induced profound QRS widening, although exhibiting weak inhibition of NaV1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!